PEP-Therapy, a biotechnology company, member of the Genopole biocluster, which develops innovative peptides as targeted therapies, has achieved a second fundraising of €1.2 million. This investment, made by the Quadrivium 1 seed fund and Dr Bernard Majoie, and based on the results obtained so far, will enable PEP-Therapy to continue the development of its products portfolio, especially to undertake the regulatory development of PEP-010 associated with its biomarker to foresee the efficacy of the treatment.